trending Market Intelligence /marketintelligence/en/news-insights/trending/t7r5olS6ewYbvE5fu9lDcQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Galera Therapeutics files for $86.3M IPO on Nasdaq

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Galera Therapeutics files for $86.3M IPO on Nasdaq

Galera Therapeutics Inc. filed for an IPO of its common shares to raise up to $86.3 million in gross proceeds.

The company applied to list its shares on the Nasdaq Global Market under the GRTX symbol.

The Malvern, Pa.-based company is developing a pipeline of therapeutics intended to reduce the normal tissue toxicity of radiotherapy, while increasing its anti-cancer efficacy.

Net proceeds from the IPO will be partly used to further develop Galera's lead product candidate GC4419, a potential therapy for reducing severe oral mucositis, a side effect of radiotherapy in patients with head and neck cancer.

A portion of the proceeds will also be used to develop GC4419 as a therapy to reduce the incidence of radiotherapy-induced esophagitis, or inflammation of the esophagus, in a planned phase 2a trial.

The company will also fund the clinical advancement of GC4711, an investigational drug for patients with non-small cell lung cancer undergoing stereotactic body radiation therapy, which delivers very intense doses of radiation to cancer cells while minimizing damage to healthy tissue.

The rest of the proceeds will be used for new and ongoing research and development activities for the company's other drug candidates, as well as for working capital and other corporate purposes.

Bank of America Merrill Lynch, Citigroup, Credit Suisse and BTIG are underwriters of the offering.